AI assistant
OptimizeRx Corp — Director's Dealing 2025
May 19, 2025
33090_dirs_2025-05-19_dd31a765-b043-4d56-9df7-83f83abc009e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: OptimizeRx Corp (OPRX)
CIK: 0001448431
Period of Report: 2025-05-15
Reporting Person: Greco Theresa (Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-05-15 | Common Stock | A | 2441 | — | Acquired | 53314 | Direct |
| 2025-05-15 | Common Stock | A | 7042 | — | Acquired | 60356 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-05-15 | Stock Option | $10.65 | A | 12133 | Acquired | 2028-05-15 | Common Stock (12133) | Direct |
Footnotes
F1: Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest on May 15, 2026, which is the anniversary of the date of the grant.
F2: Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in three equal annual installments beginning on May 15, 2026, which is the first anniversary of the date of the grant.
F3: The stock option vests in three equal annual installments beginning May 15, 2026, the first anniversary of the grant date.